In addition, silent RhoA could attenuate the expression of N-Cad and Vimentin, and enhance the expression of E-Cad in BPH-1 cells, while overexpression of RhoA reversed these EMT markers, suggesting the potential anti-fibrosis and EMT effects of RhoA downregulation. The gene discussed is RHOA; the disease is benign prostatic hyperplasia.